Latest Public Health News

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

Bio-Gene Technology’s novel acaricide Flavocide demonstrated over 90% mortality against Lyme disease-carrying ticks in lab tests presented by Purdue University, highlighting its potential in public health applications.

Island Pharmaceuticals has won a crucial FDA Type C meeting to discuss fast-tracking its antiviral Galidesivir for Marburg virus treatment, with written feedback expected by November.

Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Moab Minerals is progressing its Manyoni uranium project with a planned JORC-compliant resource estimate and is nearing completion of a key tenement acquisition, while securing fresh funding to support ongoing exploration.

UNITH Ltd reported a record quarterly cash receipt of $1.6 million in Q4 FY25, driven by strategic partnerships and platform innovations. The company is poised for growth with a new website launch and expanded European presence.